Shares of Waldencast PLC (NASDAQ:WALD – Get Free Report) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $4.4167.
WALD has been the subject of a number of recent analyst reports. Canaccord Genuity Group decreased their price target on shares of Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Waldencast in a research note on Wednesday, January 21st. Jefferies Financial Group began coverage on shares of Waldencast in a research report on Wednesday, January 14th. They issued a “buy” rating and a $2.00 target price for the company. Finally, Telsey Advisory Group lowered shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 target price on the stock. in a research note on Tuesday, November 25th.
Read Our Latest Research Report on Waldencast
Institutional Inflows and Outflows
Waldencast Stock Up 0.6%
Shares of Waldencast stock opened at $1.75 on Thursday. Waldencast has a 1-year low of $1.45 and a 1-year high of $4.10. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.67 and a current ratio of 1.53. The business has a 50-day moving average of $2.01 and a 200-day moving average of $1.94.
Waldencast (NASDAQ:WALD – Get Free Report) last issued its quarterly earnings results on Monday, November 24th. The company reported ($0.69) EPS for the quarter. The company had revenue of $66.14 million during the quarter. On average, sell-side analysts anticipate that Waldencast will post -0.14 EPS for the current year.
Waldencast Company Profile
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.
See Also
- Five stocks we like better than Waldencast
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.
